New combo therapy shows promise for tough lung cancer
NCT ID NCT04526691
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This early-stage study tests a new drug combination (datopotamab deruxtecan plus pembrolizumab, with or without chemo) in 145 people with advanced or metastatic non-small cell lung cancer. The goal is to see if the treatment is safe and can shrink tumors or slow disease progression. Participants must have a confirmed diagnosis and meet specific genetic testing requirements.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
(CIOCC-START) Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
Azienda Ospedaliera San Gerardo
Monza, 20052, Italy
-
Chung Shan Medical University Hospital
Taichung, 40201, Taiwan
-
City of Hope
Duarte, California, 91010, United States
-
H. Vall Hebrón (Vall Hebron Institut de Oncologia - VHIO)
Barcelona, 08035, Spain
-
Hospital Puerta de Hierro
Majadahonda, 28222, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Instituto Europeo Di Oncologica
Milan, 20141, Italy
-
Istituto Nazionale Tumori Fondazione G. Pascale di Napoli Struttura di Oncologia
Naples, 80131, Italy
-
Johns Hopkins Kimmel Cancer Center
Washington D.C., District of Columbia, 20016, United States
-
Johns Hopkins Kimmel Cancer Center at Bayview
Baltimore, Maryland, 21224, United States
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, 277-8577, Japan
-
National Cheng Kung University Hospital NCKUH
Tainan, 704, Taiwan
-
National Taiwan University Hospital NTUH
Taipei, 100, Taiwan
-
Quantum Santa Fe
Santa Fe, New Mexico, 87505, United States
-
START Madrid - Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Showa Medical University Hospital
Tokyo, 142-8555, Japan
-
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
-
The Skip Viragh Outpatient Cancer Building
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.